PFE vs the Top Picks average
| Pillar | PFE | Book avg | Diff |
|---|---|---|---|
| Quality | 0.66 | 0.84 | -0.18 |
| Growth | 0.14 | 0.87 | -0.73 |
| Value | 0.27 | 0.76 | -0.49 |
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
| 30-day change | +2.2% |
|---|---|
| 90-day change | +2.1% |
| Forward EPS estimate | $2.90 |
Over the last 90 days, what analysts expect PFE to earn is drifting higher (+2.1%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Pfizer Inc. (PFE): score, valuation & FAQ
Pfizer Inc. (PFE) is a Drug Manufacturers - General company that scores 29.5 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are FCF (A-), while Rev (D+) rate weaker. On valuation, PFE sits about 13% above our discounted-cash-flow fair value — the current price implies roughly 3% annual free-cash-flow growth over the next decade.
Is PFE a good stock to buy?
Bull Rankings scores PFE 29.5 out of 100 on its quality-growth model, which is a weak reading. That is driven by FCF (A-). A score is a quantitative screen of Pfizer Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does PFE score 29.5 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). PFE earns its highest marks on FCF (A-), and is held back by Rev (D+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is PFE overvalued or undervalued?
Based on $27.97, PFE sits about 13% above our discounted-cash-flow fair value — the current price implies roughly 3% annual free-cash-flow growth over the next decade. It trades at a 36.8x P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in PFE?
Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Dividend payout 226% of earnings on a 6.1% yield — distribution coverage is thin; one earnings stumble could force a dividend cut. Trailing P/E 37x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.